Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS

•Distinct peripheral T-cell and NK-cell phenotypes exist in patients with HGBL-MYC/BCL2 vs patients with DLBCL NOS without MYC rearrangements.•Patients with HGBL-MYC/BCL2 encompass exhausted PD-1+ T cells without other immune effector cell impairments. [Display omitted] Patients with high-grade B-ce...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood advances 2024-03, Vol.8 (5), p.1094-1104
Hauptverfasser: de Jonge, A. Vera, Duetz, Carolien, Bruins, Wassilis S. C., Korst, Charlotte L. B. M., Rentenaar, Rosa, Cosovic, Meliha, Eken, Merve, Twickler, Inoka, Nijland, Marcel, van der Poel, Marjolein W. M., de Heer, Koen, Klerk, Clara P. W., Strobbe, Leonie, Oosterveld, Margriet, Boersma, Rinske, Koene, Harry R., Roemer, Margaretha G. M., van Werkhoven, Erik, Chamuleau, Martine E. D., Mutis, Tuna
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Distinct peripheral T-cell and NK-cell phenotypes exist in patients with HGBL-MYC/BCL2 vs patients with DLBCL NOS without MYC rearrangements.•Patients with HGBL-MYC/BCL2 encompass exhausted PD-1+ T cells without other immune effector cell impairments. [Display omitted] Patients with high-grade B-cell lymphoma with MYC and BCL2 rearrangements (HGBL-MYC/BCL2) respond poorly to immunochemotherapy compared with patients with diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) without a MYC rearrangement. This suggests a negative impact of lymphoma-intrinsic MYC on the immune system. To investigate this, we compared circulating T cells and natural killer (NK) cells of patients with HGBL-MYC/BCL2 (n = 66), patients with DLBCL NOS (n = 53), and age-matched healthy donors (HDs; n = 16) by flow cytometry and performed proliferation, cytokine production, and cytotoxicity assays. Compared with HDs, both lymphoma subtypes displayed similar frequencies of CD8+ T cells but decreased CD4+ T cells. Regulatory T-cell (Treg) frequencies were reduced only in patients with DLBCL NOS. Activated (HLA-DR+/CD38+) T cells, PD-1+CD4+ T cells, and PD-1+Tregs were increased in both lymphoma subtypes, but PD-1+CD8+ T cells were increased only in HGBL-MYC/BCL2. Patients with DLBCL NOS, but not patients with HGBL-MYC/BCL2, exhibited higher frequencies of senescent T cells than HDs. Functional assays showed no overt differences between both lymphoma groups and HDs. Deeper analyses revealed that PD-1+ T cells of patients with HGBL-MYC/BCL2 were exhausted with impaired cytokine production and degranulation. Patients with DLBCL NOS, but not patients with HGBL-MYC/BCL2, exhibited higher frequencies of NK cells expressing inhibiting receptor NKG2A. Both lymphoma subtypes exhibited lower TIM-3+– and DNAM-1+–expressing NK cells. Although NK cells of patients with HGBL-MYC/BCL2 showed less degranulation, they were not defective in cytotoxicity. In conclusion, our results demonstrate an increased exhaustion in circulating T cells of patients with HGBL-MYC/BCL2. Nonetheless, the overall intact peripheral T-cell and NK-cell functions in these patients emphasize the importance of investigating potential immune evasion in the microenvironment of MYC-rearranged lymphomas.
ISSN:2473-9529
2473-9537
2473-9537
DOI:10.1182/bloodadvances.2023011687